KD Pharma Group acquires Marine Lipids from dsm-firmenich

Berlin — KD Pharma Group (“KD Pharma”), a leading CDMO in the field of phar­maceu­ti­cal and nutri­tio­nal lipids and port­fo­lio company of Capi­ton, announ­ces the acqui­si­tion of the Marine Lipids busi­ness of dsm-firmenich.
As part of the tran­sac­tion, dsm-firmenich will acquire a mino­rity stake in KD Pharma and become a co-share­hol­­der along­side the Capi­ton Omega Conti­nua­tion Fund vehic­les and other mino­rity shareholders.
The tran­sac­tion will close during 2024, subject to custo­mary regu­la­tory appr­ovals, and includes dsm-firmenich’s Marine Lipids fish oil omega‑3 busi­ness for the dietary supple­ment and phar­maceu­ti­cal markets, toge­ther with the manu­fac­tu­ring faci­li­ties in Piura, Peru, and Mulgrave, Canada.
This tran­sac­tion will create a well-equip­­ped player in the marine lipids market by combi­ning the best of the two compa­nies and their respec­tive exper­tise with the scale of dsm-firmenich’s sites in Piura and Mulgrave and the high concen­tra­tion capa­bi­lity of KD Pharma.
The enlar­ged KD Pharma Group will bene­fit from the expan­ded product range and custo­miza­tion capa­bi­li­ties supported by the increased produc­tion capacity.
Oscar Groet, CEO of KD Pharma, said: “We are deligh­ted to welcome dsm-firmenich’s Marine Lipids port­fo­lio to KD Pharma, a move that fits perfectly with our stra­te­gic vision to become the tech­no­logy leader in lipids.”
Further infor­ma­tion can be found at KD Pharma Group News.
https://kdpharmagroup.com/ capi­ton AG and KD Pharma Group were advi­sed by Jeffe­ries as buyer advi­sor, CMS Hasche Sigle, Baker McKen­zie, A&O Shear­man, EY, BDO, Herter & Co.
— A Teneo Company, Roland Berger and Howden M& A.
The tran­sac­tion was nota­ri­zed by Dr. Patrick Auer­bach (NEON) and is subject to custo­mary regu­la­tory approvals.